 MT110 is a bispecific anti-EpCAM x anti-CD3 T-cell engager BiTE designed to link EpCAM epithelial cell adhesion molecule expressing cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against EpCAM cells. In vitro and ex-vivo data indicate that EpCAM tumor cell lines are sensitive to MT110 mediated cytotoxicity. Furthermore, data from in-vivo experiments with both MT110 and a mouse surrogate molecule muS110 have confirmed the activity of these molecules in inhibiting the formation of metastases but also against established tumors. In vitro and ex-vivo data suggest that a prolonged presence of the drug in target tissues may result in significant T-cell recruitment, activation and expansion toin target tissues, potentially resulting in substantial anti-tumor activity in man. 